Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Autoantibody Targets Identified in Lupus Patients

By Labmedica International staff writers
Posted on 09 Dec 2013
Image: Blood smear showing an “LE cell” from a patient with systemic lupus erythematosus (Photo courtesy of Imperial College London).
Image: Blood smear showing an “LE cell” from a patient with systemic lupus erythematosus (Photo courtesy of Imperial College London).
Patients with the autoimmune disease systemic lupus erythematosus (SLE) produce autoantibodies that can cause damage to multiple organ systems.

A microarray has been developed to identify cytokines, chemokines, and other circulating proteins as potential targets of the autoantibodies produced by SLE patients, and are implicated in inflammatory autoimmune disease and diseases of immune deficiency.

Scientists at Stanford University (CA, USA) and their colleagues from other institutes designed a nitrocellulose-surface microarray containing human cytokines, chemokines, and other circulating proteins and demonstrated that the array permitted specific detection of serum factor-binding probes. They used antibody binding assays and an indirect B cell-activating factor (BAFF) enzyme-linked immunoassay to detect autoantibodies.

Serum profiling from individuals with SLE revealed that among several targets, elevated immunoglobulin G (IgG) autoantibody reactivity to BAFF was associated with SLE compared with control samples. BAFF reactivity correlated with the severity of disease-associated features, including interferon (IFN)-α–driven SLE pathology. Of the other novel targets of autoantibodies they identified, the observed reactivity to the growth factors epidermal growth factor, (EGF), and somatotropin (HGH) were of particular interest.

Further screening of samples derived from individuals with SLE and other inflammatory autoimmune diseases revealed striking array reactivity to these and other growth factor targets, including various isoforms of fibroblast growth factor (FGF). The idea of an inverse relationship between inflammation- and growth factor-mediated pathways is an area of increasing interest in the field of inflammation.

The authors concluded that the implication of growth factor-targeted autoantibodies in the potential trade-off between tissue growth/repair and inflammation is one intriguing avenue to pursue. That serum factor-protein microarrays facilitated the detection of autoantibody reactivity to serum factors in human samples and that BAFF-reactive autoantibodies may be associated with an elevated inflammatory disease state within the spectrum of SLE. The study was published on November 25, 2013, in the Journal of Clinical Investigation.

Related Links:

Stanford University



PURITAN MEDICAL
Sekisui Diagnostics
EUROIMMUN AG
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.